Prothena posted a Q2 net loss of USD 18.6 million, narrowing from a USD 125.8 million loss a year earlier; revenue fell to USD 1 million from USD 4.4 million.
R&D expense dropped to USD 8.8 million from USD 40.5 million; G&A declined to USD 10.9 million from USD 15.9 million.
First-half performance improves and cash position remains strong
First-half results swung to net income of USD 14.1 million from a loss of USD 186 million; revenue rose to USD 52.1 million from USD 7.2 million.
Cash, cash equivalents and restricted cash totaled USD 289.1 million at June 30, 2026; net cash used in operating and investing activities was USD 25.7 million in Q2.
Guidance targets year-end cash of about USD 259 million (midpoint); Roche PADOVA results for prasinezumab were published in The Lancet, with Phase 3 PARAISO primary completion expected in 2029.
PRTA•
